[ XXXX marked leukocytes: a method for diagnosing the location and evaluating the activity of @entity30 and @entity31 ].

@entity1 @entity644 @entity625 @entity31 @entity30 @entity29 @entity1595 @entity2550 @entity4769 @entity1744 @entity4344
@entity1 with @entity30 (n = 22), @entity31 (n = 5), inactive @entity1595 (n = 1), @entity1744 (n = 2), @entity625 (n = 1) and @entity2550 (n = 2) were examined with 111In- @entity4344 labelled "mixed" leukocyte preparations (n = 12) or with @entity4769 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity1 there was a correct location of infiltrated bowel segments in 24 @entity1 (78%). The scan diagnosed more infiltrated segments in 4 @entity1 (13%). In 3 @entity1 it failed to diagnose one inflamed segment. In 24 @entity1 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity1 with non @entity29 and @entity1 with inactive @entity29 excreted less than 2% of the reinjected 111In-activity. All but one female @entity1 with active @entity29 excreted more than 2%. In 24 @entity1 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity644 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity1 with @entity29 , compared to usually performed radiological, endoscopical and clinical methods.
